TransMedics Group, Inc. (NASDAQ:TMDX) CEO Waleed H. Hassanein Sells 30,000 Shares

TransMedics Group, Inc. (NASDAQ:TMDX) CEO Waleed H. Hassanein sold 30,000 shares of the firm’s stock in a transaction on Monday, May 6th. The shares were sold at an average price of $130.07, for a total value of $3,902,100.00. Following the transaction, the chief executive officer now owns 61,643 shares of the company’s stock, valued at $8,017,905.01. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

TransMedics Group Stock Down 0.0 %

TMDX stock opened at $127.22 on Thursday. The business’s 50-day moving average is $88.31 and its two-hundred day moving average is $78.91. The company has a market cap of $4.19 billion, a price-to-earnings ratio of -374.18 and a beta of 1.87. TransMedics Group, Inc. has a fifty-two week low of $36.42 and a fifty-two week high of $132.96. The company has a debt-to-equity ratio of 3.18, a quick ratio of 8.76 and a current ratio of 9.72.

TransMedics Group (NASDAQ:TMDX) last issued its quarterly earnings data on Tuesday, April 30th. The company reported $0.35 earnings per share for the quarter, topping the consensus estimate of ($0.05) by $0.40. The firm had revenue of $96.90 million for the quarter, compared to analysts’ expectations of $83.78 million. TransMedics Group had a negative net margin of 3.43% and a positive return on equity of 7.95%. The business’s quarterly revenue was up 132.9% on a year-over-year basis. During the same quarter in the prior year, the business earned ($0.08) EPS. As a group, analysts forecast that TransMedics Group, Inc. will post 0.62 earnings per share for the current year.

Wall Street Analysts Forecast Growth

TMDX has been the subject of several recent analyst reports. TD Cowen lifted their target price on shares of TransMedics Group from $100.00 to $130.00 and gave the stock a “buy” rating in a report on Wednesday, May 1st. Piper Sandler reaffirmed an “overweight” rating and issued a $120.00 price objective (up from $95.00) on shares of TransMedics Group in a research report on Wednesday, May 1st. JPMorgan Chase & Co. increased their target price on TransMedics Group from $105.00 to $127.00 and gave the company an “overweight” rating in a research note on Wednesday, May 1st. Oppenheimer upped their price target on TransMedics Group from $105.00 to $125.00 and gave the company an “outperform” rating in a report on Wednesday, May 1st. Finally, Morgan Stanley boosted their target price on TransMedics Group from $75.00 to $95.00 and gave the stock an “equal weight” rating in a research report on Wednesday, February 28th. One analyst has rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $119.00.

Institutional Investors Weigh In On TransMedics Group

A number of hedge funds have recently modified their holdings of the business. State Board of Administration of Florida Retirement System grew its stake in shares of TransMedics Group by 8.6% during the 1st quarter. State Board of Administration of Florida Retirement System now owns 9,843 shares of the company’s stock valued at $745,000 after acquiring an additional 780 shares during the period. Entropy Technologies LP purchased a new position in TransMedics Group during the first quarter valued at approximately $201,000. ProShare Advisors LLC boosted its position in shares of TransMedics Group by 7.8% in the first quarter. ProShare Advisors LLC now owns 5,871 shares of the company’s stock worth $434,000 after purchasing an additional 427 shares during the period. Russell Investments Group Ltd. increased its stake in shares of TransMedics Group by 337,462.5% in the first quarter. Russell Investments Group Ltd. now owns 27,005 shares of the company’s stock worth $1,997,000 after purchasing an additional 26,997 shares in the last quarter. Finally, Oppenheimer & Co. Inc. raised its position in shares of TransMedics Group by 156.6% during the 1st quarter. Oppenheimer & Co. Inc. now owns 26,570 shares of the company’s stock valued at $1,965,000 after purchasing an additional 16,214 shares during the period. Institutional investors own 99.67% of the company’s stock.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.